A groundbreaking new test set to significantly transform the diagnostic approach for pre-eclampsia detection.
The Lepzi PLGF test, a groundbreaking point-of-care solution developed by Una Health, is poised to revolutionise the way pre-eclampsia is diagnosed and managed in maternity units across the UK. This innovative test, which measures the level of Placental Growth Factor (PLGF) in maternal blood, has demonstrated excellent performance in diagnosing and ruling out pre-eclampsia.
Pre-eclampsia, a serious pregnancy complication characterised by high blood pressure and damage to organs such as the kidneys, can be life-threatening if not detected and managed promptly. The Lepzi PLGF test, by offering quick and accurate results, could significantly improve early detection and prognosis of the condition.
The test, performed directly from EDTA whole blood in just 15 minutes, measures the level of PLGF - a protein involved in the development of blood vessels in the placenta. Low PLGF levels are associated with pre-eclampsia, making this test a valuable tool in identifying women at higher risk before clinical symptoms appear.
By quantifying PLGF, clinicians can engage in risk stratification, identifying women at higher risk for severe pre-eclampsia and planning closer monitoring and early interventions. Furthermore, PLGF levels correlate with disease severity, providing valuable insight into the potential outcomes and guiding decisions about the timing of delivery to optimise maternal and fetal health.
The Lepzi PLGF test by Una Health is supported by Una Health, a company that aims to drive change in women's health and improve efficiency in healthcare services. The test requires no laboratory equipment, making it an accessible diagnostic tool for obstetric care.
The study supporting the Lepzi PLGF test has shown that it can be used for determining which women are likely to need delivery for pre-eclampsia within 7, 14, and 28 days. This test could enable safe discharge of women from healthcare facilities, reducing unnecessary monitoring.
Una Health has partnered with Lepzi Ltd to become the UK distributor for the new Lepzi PLGF test. Naomi Chant, Commercial Director of POCT at Una Health, has expressed her commitment to improving outcomes for patients and healthcare services with the Lepzi PLGF test. Professor Andrew Shennan of King's College London stated that the Lepzi test delivers a step-change in the diagnosis and prognosis of pre-eclampsia.
Una Health is excited to be part of the rollout of the Lepzi PLGF test, which represents a significant advancement in the field of pre-eclampsia testing. For official, detailed product information or clinical data on the Lepzi PLGF test from Una Health, I recommend consulting Una Health’s official resources or clinical publications directly.
- The 'Femtech news' is buzzing about the Lepzi PLGF test, a point-of-care solution developed by Una Health, which has the potential to revolutionize the management and early detection of pre-eclampsia, a serious medical-condition in women during pregnancy.
- With the advancements in science, this 'health-and-wellness' innovation could significantly reduce the risks associated with pre-eclampsia, a pregnancy complication characterized by high blood pressure and damage to organs such as the kidneys, and potentially life-threatening if not detected promptly.
- The Lepzi PLGF test, involving the measurement of Placental Growth Factor (PLGF) in maternal blood, offers quick and accurate results, enabling clinicians to engage in 'womens-health' risk stratification, identify women at higher risk for severe pre-eclampsia, and make informed decisions about the timing of delivery to optimize maternal and fetal health.
